Statements (246)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:chemical_compound |
| gptkbp:administered_by |
injection
oral tablet various dosages |
| gptkbp:biological_target |
intestinal flora
|
| gptkbp:cause |
mood regulation
|
| gptkbp:chemical_formula |
C20 H25 N3 O2 S
|
| gptkbp:class |
psychoactive substances
biologic therapy |
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:Phase_4 gptkb:Asia gptkb:Canada gptkb:USA gptkb:United_States gptkb:MRX_Pharmaceuticals 12 months Phase 1 Phase 2 Phase 3 anxiety and depression multiple centers promising efficacy Medi Rox diagnosed with RA |
| gptkbp:collaboration |
clinical research organizations
|
| gptkbp:collaborations |
gptkb:pharmaceuticals
academic institutions Biotech Company |
| gptkbp:collaborator |
gptkb:National_Institutes_of_Health
gptkb:National_Health_Institute |
| gptkbp:competitors |
Drug A
Drug B Drug C other RA therapies |
| gptkbp:composed_by |
precursor compounds
|
| gptkbp:conducts_research_on |
neuroplasticity
psychiatric disorders mental health innovations mental health treatments |
| gptkbp:contraindication |
hypersensitivity
|
| gptkbp:criteria |
pregnant women
severe liver disease |
| gptkbp:developed_by |
gptkb:MRX_Pharmaceuticals
Medi Rox Microbiome Therapeutics |
| gptkbp:dosage_form |
gptkb:Software_Solutions
once daily based on weight weight-based |
| gptkbp:drug_interactions |
antibiotics
anticoagulants antidepressants immunosuppressants anticonvulsants |
| gptkbp:duration |
long-term therapy
|
| gptkbp:effective_date |
not yet approved
|
| gptkbp:eligibility |
18 years and older
diagnosed with multiple sclerosis |
| gptkbp:feedback |
generally positive
some concerns about side effects |
| gptkbp:financial_support |
available resources
|
| gptkbp:formulation |
gptkb:tablet
gptkb:capsule probiotic sterile solution |
| gptkbp:funding |
government grants
private funding private investment private investors government grant |
| gptkbp:future_prospects |
long-term effects
combination therapies |
| gptkbp:has_potential_effect |
gptkb:depression
|
| gptkbp:healthcare |
limited in some regions
|
| gptkbp:healthcare_provider_role |
monitor treatment progress
|
| https://www.w3.org/2000/01/rdf-schema#label |
MRx0005
|
| gptkbp:indication |
gptkb:Crohn's_disease
gptkb:ulcerative_colitis autoimmune diseases |
| gptkbp:ingredients |
MRx0005 compound
|
| gptkbp:interacts_with |
other immunosuppressants
|
| gptkbp:invention |
patented
|
| gptkbp:investigates |
gptkb:Dr._Jane_Doe
gptkb:Dr._John_Smith gptkb:Dr._Smith gptkb:Dr._Johnson bipolar disorder clinical settings |
| gptkbp:investment |
high
|
| gptkbp:is_associated_with |
improved mood
|
| gptkbp:is_considered |
combination therapy
treatment protocols |
| gptkbp:is_considered_as |
novel antidepressant
|
| gptkbp:is_considered_as_alternative_to |
traditional antidepressants
|
| gptkbp:is_effective_against |
under investigation
mood disorders |
| gptkbp:is_evaluated_by |
chronic pain
preclinical studies long-term effects |
| gptkbp:is_evaluated_for_impact_on |
quality of life
|
| gptkbp:is_evaluated_for_safety_in |
human trials
|
| gptkbp:is_in_phase |
clinical trials
|
| gptkbp:is_influential_in |
brain chemistry
|
| gptkbp:is_investigated_for_potential_use_in |
addiction treatment
|
| gptkbp:is_investigated_for_use_in |
gptkb:psychotherapy
|
| gptkbp:is_known_for |
high selectivity
|
| gptkbp:is_linked_to |
neurotransmitter systems
|
| gptkbp:is_monitored_by |
liver function tests
|
| gptkbp:is_part_of |
pharmaceutical research
drug development pipeline neuropharmacology research |
| gptkbp:is_patent_protected |
yes
|
| gptkbp:is_related_to |
serotonin receptors
|
| gptkbp:is_reported_to_have_effect_on |
cognitive function
|
| gptkbp:is_reported_to_interact_with |
other medications
|
| gptkbp:is_reported_to_show |
promising results
|
| gptkbp:is_studied_for |
gptkb:neurodegenerative_diseases
anxiety disorders |
| gptkbp:is_studied_for_effectiveness_in |
treatment-resistant depression
|
| gptkbp:is_studied_for_potential_in |
cognitive behavioral therapy.
|
| gptkbp:is_studied_in |
animal models
|
| gptkbp:is_subject_to |
regulatory approval
|
| gptkbp:is_targeted_at |
gptkb:depression
|
| gptkbp:is_tested_for |
gptkb:Clinical_Trials
clinical trials |
| gptkbp:is_under_research_for |
PTSD
|
| gptkbp:is_used_in |
gptkb:medical_research
emergency psychiatry |
| gptkbp:market_position |
not yet approved
not yet marketed |
| gptkbp:marketed_as |
gptkb:Europe
gptkb:United_States brand name X |
| gptkbp:mechanism_of_action |
modulates immune response
serotonin reuptake inhibition immune modulation inhibits immune response inhibits inflammatory cytokines modulates gut microbiota |
| gptkbp:participants |
quality of life assessment
reduction in relapse rate |
| gptkbp:patient_education |
important for understanding treatment
|
| gptkbp:patient_population |
adults
|
| gptkbp:pharmacokinetics |
immune modulation
half-life 10 days |
| gptkbp:price |
high cost
|
| gptkbp:production_status |
in development
|
| gptkbp:provides_guidance_on |
follow rheumatology guidelines
|
| gptkbp:publication |
gptkb:Journal_of_Neurology
gptkb:Clinical_Trials_Journal peer-reviewed journals |
| gptkbp:regulatory_body |
gptkb:FDA
gptkb:European_Medicines_Agency |
| gptkbp:regulatory_compliance |
pending
FDA approved |
| gptkbp:reported_by |
low toxicity
|
| gptkbp:research |
randomized controlled trial
double-blind study placebo-controlled trial |
| gptkbp:research_focus |
gptkb:systemic_lupus_erythematosus
rheumatology neurological disorders lupus nephritis microbiome therapy |
| gptkbp:research_institutes |
gptkb:University_of_Alberta
University of Medicine |
| gptkbp:research_output |
improved quality of life
patient compliance ongoing studies enhanced quality of life cost-effectiveness analysis patient-reported outcomes healthcare utilization dose-response relationship clinical efficacy reduced inflammation biomarker analysis promising results long-term safety reduced disease activity improved symptoms further studies needed safety and tolerability microbiome analysis adverse event monitoring healthcare provider feedback long-term safety concerns patient adherence issues pharmacodynamics study pharmacokinetics study potential market entry preliminary results tolerability assessment |
| gptkbp:research_phase |
Phase 1
Phase 3 preclinical |
| gptkbp:research_status |
ongoing studies
|
| gptkbp:route_of_administration |
oral
subcutaneous |
| gptkbp:safety_features |
under investigation
generally well tolerated under evaluation |
| gptkbp:safety_measures |
post-marketing surveillance
|
| gptkbp:service_frequency |
daily
once a month |
| gptkbp:side_effect |
dizziness
fatigue headache nausea allergic reactions rash injection site reactions gastrointestinal discomfort liver function abnormalities injection site reaction increased infection risk blood pressure changes kidney function abnormalities |
| gptkbp:status |
investigational
|
| gptkbp:storage |
refrigerated
|
| gptkbp:supply_chain |
managed by MRX Pharmaceuticals
|
| gptkbp:target_audience |
gptkb:children
adults patients with multiple sclerosis |
| gptkbp:target_mechanism |
T-cell modulation
|
| gptkbp:targets |
gptkb:TNF-alpha
autoimmune diseases immune system gut microbiome |
| gptkbp:treatment |
improved quality of life
reduced symptoms disease remission |
| gptkbp:type |
gptkb:monoclonal_antibody
biologic |
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:type_of_insurance |
varies by plan
|
| gptkbp:used_for |
gptkb:disease
gptkb:Canis_lupus gptkb:rheumatoid_arthritis gptkb:multiple_sclerosis psoriasis |
| gptkbp:weight |
375.5 g/mol
|
| gptkbp:bfsParent |
gptkb:4_D_Pharma
|
| gptkbp:bfsLayer |
6
|